Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (âSenti Bioâ), a clinical-stage biotechnology company developing next-generation cell and gen...
How might upcoming macroâeconomic or market factors (e.g., interest rate changes, biotech sector sentiment) influence the stock's reaction to the news?
What is the potential upside or downside for the stock if the Phase 1 data is positive vs. negative?
How does the pipeline's overall timeline (including other INDâenabling studies) affect the company's longâterm valuation and risk profile?
21 days ago